Biblio

Author Title Type [ Year(Asc)]
Filters: Author is Halkes, Constantijn J M  [Clear All Filters]
2024
Borne PAVon Dem, Kemps-Mols BM, de Wreede LC, van Beek AA, Snijders TJF, van Lammeren D, Tijmensen J, Sijs-Szabo A, Oudshoorn MA, Halkes CJM, et al. The degree of HLA matching determines the incidence of cytokine release syndrome and associated nonrelapse mortality in matched related and unrelated allogeneic stem cell transplantation with post-transplant cyclophosphamide. Leuk Lymphoma. 2024:1-11.
Lommerse IN, Hinnen C, van Vliet LM, Schubert B, Panse J, Halkes CJM, Tjon JM-L. Quality of life after immune suppressive therapy in aplastic anemia. Ann Hematol. 2024.
Koster EAS, Borne PAVon Dem, van Balen P, Marijt EWA, Tjon JML, Snijders TJF, van Lammeren D, Veelken H, Falkenburg JHFrederik, Halkes CJM, et al. Risk factors for graft-versus-host-disease after donor lymphocyte infusion following T-cell depleted allogeneic stem cell transplantation. Front Immunol. 2024;15:1335341.
2023
Sijs-Szabo A, Dinmohamed AG, Versluis J, van der Holt B, Bellido M, Hazenberg MD, van Gelder M, Schaap NPM, Meijer E, van der Wagen LE, et al. Allogeneic Stem Cell Transplantation in Patients >40 Years of Age With Acute Lymphoblastic Leukemia: Reduced Intensity Versus Myeloablative Conditioning. Transplantation. 2023.
Devillier R, Eikema D-J, Dufour C, Aljurf M, Wu D, Maschan A, Kulagin A, Halkes CJM, Collin M, Snowden J, et al. Graft-versus-host disease and relapse/rejection-free survival after allogeneic transplantation for idiopathic severe aplastic anemia: a comprehensive analysis from the SAAWP of the EBMT. Haematologica. 2023.
Koster EAS, Bonneville EF, Borne PA von dem, van Balen P, Marijt EWA, Tjon JML, Snijders TJF, van Lammeren D, Veelken H, Putter H, et al. Joint models quantify associations between immune cell kinetics and allo-immunological events after allogeneic stem cell transplantation and subsequent donor lymphocyte infusion. Front Immunol. 2023;14:1208814.
2022
Koster EAS, Borne PAVon Dem, van Balen P, van Egmond EHM, Marijt EWA, Veld SAJ, Jedema I, Snijders TJF, van Lammeren D, Veelken H, et al. Competitive repopulation and allo-immunological pressure determine chimerism kinetics after T-cell depleted allogeneic stem cell transplantation and donor lymphocyte infusions. Transplant Cell Ther. 2022.
2020
Baron F, Efficace F, Cannella L, Muus P, Trisolini S, Halkes CJM, Fazi P, Vignetti M, Marie J-P, Chiusolo P, et al. Impact of the type of anthracycline and of stem cell transplantation in younger patients with acute myeloid leukaemia: long-term follow up of a phase III study. Am J Hematol. 2020.
2019
Loeff FC, van Egmond EHM, Moes DJAR, Wijnands C, Borne PAVon Dem, Veelken H, Falkenburg JHFrederik, Jedema I, Halkes CJM. Impact of alemtuzumab pharmacokinetics on T-cell dynamics, graft-versus-host disease and viral reactivation in patients receiving allogeneic stem cell transplantation with an alemtuzumab-based T-cell-depleted graft. Transpl Immunol. 2019.
Shaw A, Passweg JR, De La Fuente J, Bajwa R, Stein J, Al-Zaben A, Halkes CJM, Norton A, Cummins M, Moppett JP, et al. Relapse of aplastic anemia with majority donor chimerism (donor-type aplasia) occurring late after bone marrow transplantation. Biol Blood Marrow Transplant. 2019.